Patents by Inventor Cendrine Lemoine

Cendrine Lemoine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210260165
    Abstract: The invention relates to methods of treating a hepatitis B virus (HBV) infection in a subject in need thereof, comprising administering to the subject a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist (e.g., a an agonistic antibody directed against the receptor, a soluble TNFRSF agonist including but not limited to its natural ligand or a fragment of either) and an interferon (IFN) or a functional fragment thereof, to decrease one or more symptoms of HBV infection in the subject are provided.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 26, 2021
    Inventors: Antoine ALAM, Odile BONNIN, Kara CARTER, Julie MONTEGUT, Cendrine LEMOINE, Xavier MARNIQUET
  • Patent number: 10906978
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: February 2, 2021
    Assignee: SANOFI
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Publication number: 20200399391
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 24, 2020
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Publication number: 20200399369
    Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 8, 2020
    Publication date: December 24, 2020
    Inventors: Mangaiarkarasi ASOKAN, Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Mark CONNORS, Richard A. KOUP, Young Do KWON, Peter D. KWONG, Qingbo LIU, Paolo LUSSO, John R. MASCOLA, Gary J. NABEL, Amarendra PEGU, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
  • Publication number: 20200255540
    Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Application
    Filed: December 23, 2019
    Publication date: August 13, 2020
    Inventors: Christian Beil, Karl-Christian Engel, Gerhard Hessler, Soraya Hoelper, Christian Lange, Thomas Langer, Cendrine Lemoine, Wulf-Dirk Leuschner, Sevim Oezguer Bruederle, Ercole Rao, Nadja Spindler, Sandra Weil
  • Publication number: 20200140552
    Abstract: The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.
    Type: Application
    Filed: October 8, 2019
    Publication date: May 7, 2020
    Inventors: Lan WU, Ling XU, Edward SEUNG, Ronnie WEI, Gary NABEL, Zhi-Yong YANG, Tarik DABDOUBI, Béatrice CAMERON, Cendrine LEMOINE, Catherine PRADES
  • Publication number: 20190106504
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 11, 2019
    Inventors: Lan WU, Ling XU, Edward SEUNG, Ronnie WEI, Gary NABEL, Zhi-Yong YANG, Tarik DABDOUBI, Béatrice CAMERON, Cendrine LEMOINE, Catherine PRADES
  • Publication number: 20180222987
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Publication number: 20180127487
    Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.
    Type: Application
    Filed: October 18, 2017
    Publication date: May 10, 2018
    Inventors: Kara CARTER, Cendrine LEMOINE, Marie MANDRON, Sunghae PARK, Huawei QIU, Jonathan ROTHBLATT
  • Publication number: 20180057597
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: July 20, 2017
    Publication date: March 1, 2018
    Inventors: Jana ALBRECHT, Cédric BARRIERE, Christian BEIL, Jochen BENINGA, Chantal CARREZ, Stéphane GUERIF, Katja KROLL, Christian LANGE, Cendrine LEMOINE, Wulf-Dirk LEUSCHNER, Ercole RAO, Marion SCHNEIDER, Marie-Cécile WETZEL, Peter WONEROW
  • Patent number: 7378274
    Abstract: The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: May 27, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Marie-Françoise Rosier-Montus, Catherine Prades, Cendrine Lemoine, Laurent Naudin, Patrice Denefle, Nicolas Duverger, Bryan Brewer, Alan Remaley, Sylvia Santamarina-Fojo
  • Publication number: 20040185456
    Abstract: The invention relates to nucleic acids corresponding to different exons and introns of gene ABC1 which is shown to be a gene causing pathologies linked to cholesterol metabolism dysfunction causing diseases such as atherosclerosis, more particularly perturbation of reverse cholesterol transport and more particularly the FHD's such as Tangier Disease
    Type: Application
    Filed: June 18, 2003
    Publication date: September 23, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Patrice Denefle, Marie-Francoise Rosier-Montus, Isabelle Arnould-Reguigne, Catherine Prades, Laurent Naudin, Cendrine Lemoine, Nicolas Duverger, Stephan Rust, Gerd Assmann, Harald Funke, H. Bryan Brewer
  • Publication number: 20030087246
    Abstract: The present invention relates to a novel human ABCA12 gene as well as cDNAs encoding the novel full and short length ABCA12 proteins. The invention also relates to vectors and recombinants host cells comprising such nucleic acids, nucleotide probes and primers, and means for the detection of polymorphisms and mutations in the ABCA12 gene or in the corresponding protein produced by the allelic form of the ABCA12 gene.
    Type: Application
    Filed: February 12, 2002
    Publication date: May 8, 2003
    Inventors: Isabelle Arnould-Reguigne, Catherine Prades, Laurent Naudin, Cendrine Lemoine, Michael Dean, Patrice Denefle, Marie-Francoise Rosier-Montus
  • Publication number: 20020146792
    Abstract: The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis.
    Type: Application
    Filed: May 2, 2001
    Publication date: October 10, 2002
    Inventors: Marie-Francoise Rosier-Montus, Catherine Prades, Cendrine Lemoine, Laurent Naudin, Patrice Denefle, Nicolas Duverger, Bryan Brewer, Alan Remaley, Sylvia Santamarina-Fojo